Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

Código QR

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

Mario A Economou,1 Helene Kolstad Laukeland,2,3 Iwona Grabska-Liberek,4 Jean-François Rouland5 1Anterior Segment Department, St Erik’s Eye Hospital, Karolinska Institute, Stockholm, Sweden; 2Department of Ophthalmology, University Hospital, Trondheim, Norway; 3Department of Lab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Glaucoma prostaglandins preservative-free latanoprost patient satisfaction conjunctival hyperemia ocular surface diseases Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/73837d2e8a2542d1b4b98674f8f4ebc1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
por: Erb C, et al.
Publicado: (2021)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo H, et al.
Publicado: (2016)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck DER, et al.
Publicado: (2017)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Muñoz Negrete FJ, et al.
Publicado: (2017)

Glaucoma therapy: preservative-free for all?
por: Thygesen J
Publicado: (2018)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe T, et al.
Publicado: (2016)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe N, et al.
Publicado: (2020)

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
por: Chávez-Mondragón E, et al.
Publicado: (2019)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
por: Halder A, et al.
Publicado: (2020)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi H, et al.
Publicado: (2017)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda Y, et al.
Publicado: (2016)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes RA, et al.
Publicado: (2019)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo J, et al.
Publicado: (2016)

Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
por: Quiroz-Mercado H, et al.
Publicado: (2020)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
por: Takemoto D, et al.
Publicado: (2017)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue K, et al.
Publicado: (2020)

The use of preservatives in dry eye drops
por: Walsh K, et al.
Publicado: (2019)

Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
por: Nasser L, et al.
Publicado: (2018)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
por: Deshpande SS, et al.
Publicado: (2017)

Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
por: Pasquale LR, et al.
Publicado: (2018)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
por: Takagi Y, et al.
Publicado: (2018)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

A Retrospective Data Review Confirms That Topical Preservative-Free Hydrocortisone Improves Inflammation in Dry Eye Disease
por: Kuzmanović Elabjer B, et al.
Publicado: (2020)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin E, et al.
Publicado: (2017)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
por: Mylla Boso AL, et al.
Publicado: (2020)

Comparative Study between Topical Latanoprost versus Topical 5- Fluorouracil after Dermabrasion for Treatment of Non-Segmental Stable Vitiligo
por: Rehab Abd El Razek, et al.
Publicado: (2021)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
por: Muñoz Negrete FJ, et al.
Publicado: (2017)

Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
por: Feldman RM, et al.
Publicado: (2020)

On the pseudospectrum preservers
por: Kettani,Mustapha Ech-Chérif El, et al.
Publicado: (2020)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen J, et al.
Publicado: (2016)

Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
por: Stalmans I, et al.
Publicado: (2020)

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973–2012)
por: Mahendraraj K, et al.
Publicado: (2017)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)